In 15 years, Germany's Epigenomics has experienced a heady series of ups and downs. The Berlin-based diagnostics company went public on the Frankfurt stock exchange in 2004 and raised €41.6 million. It merged with a Seattle operation that is now its U.S. arm and gained CE marks for a colon cancer early-detection diagnostic and a lung cancer confirmatory assay. But over the last two years, there was also the restructuring. Read more >>
Early detection boosts colon cancer survival rates. The Yonsei University College of Medicine in Seoul, South Korea, and Genomictree believe they can accomplish this goal, thanks to a noninvasive biomarker blood test that appears to be highly accurate based on initial clinical work.
Using lipids derived from grapefruits, researchers at the University of Louisville have created nanoparticles for drug delivery that are less toxic to both people and the environment and may offer a less expensive alternative to synthetic materials.
A new therapeutic may be more effective against a variety of cancers--including colon, head and neck, mesothelioma, ovarian and pancreatic cancers--than previously thought.
Mode Diagnostics wants European regulatory approval in 2013 for a do-it-your-self home test for colon cancer, with an eye toward an FDA-signoff within18 months thereafter. And that's big news for the industry at large.
Researchers from a consortium in the Basque region of Spain and France have developed a compound that has stopped colon cancer metastasis in mice.
Lab21 says it is unloading its South Carolina clinical services business in order to focus more on its diagnostics business. The buyers: Local management and investors under the name Reedy Acquisitions.
Kyoto University scientists say they've successfully linked a biomarker to colon cancer stem cells in a mouse study, offering another potential way to develop a targeted cancer treatment with minimal side effects.
A pair of newly discovered genetic biomarkers from Australian company Clinical Genomics has caught the eye of Quest Diagnostics, and the diagnostics company has exercised its commercial option to license these markers to develop a new generation of blood-based colon cancer tests for the U.S. market.
A group of Spanish institutions are collaborating to develop an early test for colorectal cancer, the second-highest cause of cancer death in the Western world, killing 50,000 people every year.